Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Carbone says STK11 and KEAP1 mutations often mark immune-cold, PD-L1-negative tumors where dual immunotherapy may have extra activity. But he warns mutation testing is imperfect: many mutated STK11 tumors retain function, so high PD-L1 plus STK11 alone still pushes him toward single immunotherapy for first-line treatment.

Related Insights

Early Phase 3 trials like JAVELIN adding immunotherapy to chemoradiation failed to improve outcomes. However, subgroup analyses consistently showed a potential benefit in PD-L1 high-expressing patients, a crucial lesson that informed the design of subsequent, more successful studies.

Synthakyne's drug demonstrated a 75% response rate in lung cancer patients with STK11 and KEAP1 mutations, a subgroup where the published response rate for standard care is only 7%. This suggests the drug is highly effective in the most immunologically resistant patient populations, a significant differentiator.

Carbone points to Keynote 407 five-year data where PD-L1-negative squamous tumors did so poorly that more control-arm patients were alive than treated patients. In his practice, he uses the 9LA dual immunotherapy regimen in that setting for those patients because long-term survival with chemoimmunotherapy is unimpressive.

In PD-L1 negative KRAS-mutated lung cancer, where standard immunotherapy is less effective, adding a CTLA-4 inhibitor can recover the immune response and create long-term survivors. This makes a triplet or quadruplet regimen the current optimal strategy for this challenging patient subgroup.

Carbone says Checkmate 227 used dual immunotherapy without chemotherapy and had almost exactly the same efficacy, including in PD-L1-negative subsets. He questions whether adding chemotherapy, especially four cycles, adds much benefit, and he notes that patients in his experience often like having only two cycles.

Contrary to the standard 'TKI-first' approach for driver mutations, a study in MET exon 14 skipping NSCLC suggests a different strategy. Patients with high PD-L1 expression appeared to have better outcomes with first-line chemoimmunotherapy, reserving the targeted therapy for later. This challenges the conventional wisdom of prioritizing the driver mutation over immunotherapy biomarkers in this specific subgroup.

Despite major advances in immunotherapy, patient selection remains crude compared to targeted therapies. PD-L1 is still the primary, yet imperfect, biomarker used. Dr. Carbone highlights an urgent need to develop better predictive biomarkers to customize immunotherapy regimens, as is standard for targeted agents.

For metastatic TNBC patients with both a germline BRCA mutation and PD-L1 positivity, experts favor initiating treatment with an ADC-immunotherapy combination. The rationale is that while PARP inhibitors are superior to chemo, there is no evidence they outperform a highly effective ADC, making the combo the preferred upfront choice.

For patients with actionable mutations like EGFR or ALK, targeted therapy is the priority, regardless of PD-L1 score. Starting immunotherapy first in these patients can significantly increase the risk of developing severe pneumonitis (ILD) when they later switch to targeted therapy like osimertinib.

STK11 and KEAP1 co-mutations in KRAS-mutated NSCLC are biomarkers for aggressive disease. For these patients, a more intensive upfront treatment strategy, such as adding chemotherapy to a targeted therapy and immunotherapy combination, should be considered to combat the poor prognosis.